Should every patient with MDS get iron chelation – probably yes.

Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh
  • Kanjaksha Ghosh
    Director Surat Raktadan Kendra & Research Centre Udhna Khatodara Urban health Centre Udhna Magdalla road Surat 395002, India | kanjakshaghosh@hotmail.com
  • Emanuele Angelucci
    Affiliation not present
  • Federica Pilo
    Affiliation not present
  • Kinjalka Ghosh
    Clinical Biochemistry, KEM Hospital & Seth GS Medical College Mumbai, India,

Abstract

NA

Keywords

Anemia , MDS, Iron Overload , Chelation

Full Text:

PDF
HTML
Submitted: 2017-07-05 10:17:38
Published: 2017-09-01 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar

References

Angelucci E, Urru SA, Pilo F, Piperno A. Myelodysplastic Syndromes and Iron Chelation Therapy. Mediterr J Hematol Infect Dis. 2017 Mar 1;9:e2017021. doi: 10.4084/MJHID.2017.021. eCollection 2017.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br. Jr. Haematol. 2017.177:741-750.

Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry .Leuk Res. 2012;36:1067-70.

Shigeta S, Toyoshima M, Kitatani K, Ishibashi M, Usui T, Yaegashi N.Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Oncogene. 2016 ;35:3577-86.

Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006 ;91:1588-90.

Fibach E, Rachmilewitz EASelective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS. Leuk. Res. 2012;36:962-3.

Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF,Rachmilewitz EA, Hebbel RPDeferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood.199586:2008-13.

Cazzola M, Della Porta MG, Malcovati L.The genetic basis of myelodysplasia and its clinical relevance. Blood.2013 ;122:4021-34.

Prá D, Franke SI, Henriques JA, Fenech M.Iron and genome stability: an update. Mut. Res. 2012;733:92-9.

Gupta M, Madkaikar M, Rao VB, Mishra A, Govindaraj P, Thangaraj K, Ghosh K Mitochondrial DNA variations in myelodysplastic syndrome. Annals . Hematol.2013;92:871-6.

Reddy PL, Shetty VT, Dutt D, York A, Dar S, Mundle SD, Allampallam K, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh M, Suleman S, Kamal SY, Raza A(2002).Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br. Jour. Haematol.2002;116:564-75.

Nairz M, Schroll A, Demetz E, Tanncevski I, Theurl I, Weiss G.Ride on the ferrous wheel—The cycle of iron in macrophages in health and disease. Immunobiology, 2014. http//dx.doi.org/10.1016/j.imbio.2014.09.010.

Abstract views:
298

Views:
PDF
113
HTML
107

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Comments on this article

View all comments


Copyright (c) 2017 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185